Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Down 26.3% in March

Key Points

• Short interest fell 26.3% in March to 6,053,456 shares (about 13.7% of the stock) with a days-to-cover ratio of 2.9.
• Insiders have been net sellers recently — Director Richard Heyman and CFO Benjamin Hohl sold shares, with insiders offloading 37,460 shares (~$1.04M) over the last 90 days while still owning 25.9% of the company.
• Institutional ownership is very high at 95.08%, including large new stakes (Vestal Point now owns 3.83M shares), and the stock trades near a 1‑year high ($43.95) with a consensus rating of "Moderate Buy" and a $43.40 price target.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) was the target of a significant decline in short interest during the month of March. As of March 31st, there was short interest totaling 6,053,456 shares, a decline of 26.3% from the March 15th total of 8,215,500 shares. Based on an average trading volume of 2,117,376 shares, the days-to-cover ratio is presently 2.9 days. Currently, 13.7% of the company's stock are sold short.

Insider Transactions at Enliven Therapeutics

In other news, Director Richard A. Heyman sold 1,230 shares of the business's stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total value of $32,201.40. Following the completion of the sale, the director owned 22,647 shares of the company's stock, valued at approximately $592,898.46. The trade was a 5.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Benjamin Hohl sold 10,000 shares of the business's stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $29.58, for a total transaction of $295,800.00. Following the completion of the sale, the chief financial officer directly owned 51,000 shares of the company's stock, valued at $1,508,580. The trade was a 16.39% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 37,460 shares of company stock valued at $1,041,104. 25.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors have recently modified their holdings of ELVN. Seven Fleet Capital Management LP bought a new stake in Enliven Therapeutics in the 4th quarter valued at about $180,000. Invesco Ltd. grew its position in Enliven Therapeutics by 7.0% in the 4th quarter. Invesco Ltd. now owns 24,720 shares of the company's stock worth $381,000 after purchasing an additional 1,624 shares during the last quarter. XTX Topco Ltd grew its position in Enliven Therapeutics by 472.6% in the 4th quarter. XTX Topco Ltd now owns 60,702 shares of the company's stock worth $935,000 after purchasing an additional 50,101 shares during the last quarter. Vestal Point Capital LP increased its stake in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company's stock valued at $58,982,000 after purchasing an additional 2,670,000 shares during the period. Finally, Virtus Investment Advisers LLC increased its stake in shares of Enliven Therapeutics by 172.6% in the fourth quarter. Virtus Investment Advisers LLC now owns 15,778 shares of the company's stock valued at $243,000 after purchasing an additional 9,991 shares during the period. Institutional investors own 95.08% of the company's stock.

Enliven Therapeutics Stock Performance

Shares of Enliven Therapeutics stock traded down $0.90 on Wednesday, reaching $43.95. 865,775 shares of the company were exchanged, compared to its average volume of 1,309,876. The firm has a market cap of $2.63 billion, a price-to-earnings ratio of -23.63 and a beta of 0.26. Enliven Therapeutics has a 1-year low of $14.78 and a 1-year high of $46.31. The company's 50-day moving average is $32.42 and its two-hundred day moving average is $25.01.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.06). As a group, sell-side analysts forecast that Enliven Therapeutics will post -1.95 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on ELVN. Weiss Ratings reiterated a "sell (d-)" rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Mizuho lifted their price objective on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the stock an "outperform" rating in a report on Wednesday, March 25th. Wall Street Zen cut shares of Enliven Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, February 28th. Finally, HC Wainwright raised their price target on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the stock a "buy" rating in a research report on Thursday, March 26th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Enliven Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $43.40.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.